Evoked Potentials: Testing Nerve Signal Pathways

Evoked potential (EP) testing measures the electrical signals the nervous system generates in response to specific sensory stimuli, providing neurologists with objective data about how quickly and reliably signals travel along defined nerve pathways. Unlike imaging studies, EP testing captures the functional integrity of nerve conduction rather than its structural appearance. The technique plays a central role in diagnosing conditions such as multiple sclerosis, optic neuritis, and spinal cord lesions, and it complements the broader landscape of neurological diagnostic tools covered across this site.

Definition and scope

Evoked potentials are time-locked electrical responses recorded from scalp electrodes or peripheral sensors following a controlled sensory challenge—visual, auditory, or somatosensory. The core measurement is latency: the time, expressed in milliseconds, between stimulus delivery and the peak of each identifiable waveform component. Prolonged latency, absent waveforms, or reduced amplitude each signal disruption somewhere along the tested pathway.

The American Clinical Neurophysiology Society (ACNS) publishes technical standards that govern electrode placement, stimulus parameters, and normative latency ranges for each EP modality (ACNS Guideline Series). Because EP studies produce objective, quantifiable output, they carry evidentiary weight in both clinical diagnosis and, where relevant, medicolegal contexts. The regulatory context for neurological testing further addresses how EP studies intersect with coverage policies under CMS and professional standards from organizations such as the American Academy of Neurology (AAN).

EP testing is distinct from electroencephalography (EEG), which records spontaneous brain electrical activity, and from EMG and nerve conduction studies, which assess peripheral motor and sensory nerve function without requiring central pathway analysis.

How it works

All EP studies share a common procedural architecture, though stimulation method and recording site differ by modality.

General procedural sequence:

Electrode placement — Disc or cup electrodes are affixed to standardized scalp positions defined by the International 10–20 system, plus reference and ground electrodes at peripheral sites.
Stimulus delivery — A controlled sensory stimulus is presented repeatedly; repetition counts typically range from 100 to 2,000 trials depending on signal-to-noise requirements.
Signal averaging — Because each individual evoked response is far smaller than background EEG noise (often below 1 microvolt), a computer averages hundreds of stimulus-synchronized sweeps to extract the reproducible waveform from random noise.
Waveform identification — Technologists and neurophysiologists identify named peaks, labeled by polarity and mean latency in milliseconds (e.g., P100 in visual EP, wave V in auditory brainstem response).
Comparison to normative data — Measured latencies and inter-peak intervals are compared against age- and sex-matched normative values; deviations exceeding 2.5 to 3 standard deviations from the mean are conventionally flagged as abnormal.
Report generation — A supervising neurologist or neurophysiologist interprets the tracings in clinical context and issues a formal report.

The three principal modalities differ in stimulus type and the pathway each interrogates:

Modality	Stimulus	Primary pathway assessed	Key waveform
Visual EP (VEP)	Checkerboard pattern reversal	Optic nerve → occipital cortex	P100
Brainstem Auditory EP (BAEP)	Clicks delivered via headphones	Auditory nerve → brainstem	Waves I–V
Somatosensory EP (SSEP)	Electrical pulse to peripheral nerve	Peripheral nerve → somatosensory cortex	N20 (median nerve)

Motor evoked potentials (MEPs), generated using transcranial magnetic stimulation rather than sensory input, extend the methodology to corticospinal tract assessment and are detailed in subspecialty literature from the ACNS.

Common scenarios

EP studies are ordered when clinical examination raises suspicion of demyelination, compressive pathway injury, or subclinical lesions not visible on structural imaging.

Multiple sclerosis — VEP is the most diagnostically powerful single EP test for MS. A P100 latency exceeding 115 milliseconds, or an interocular latency difference greater than 8 milliseconds, indicates slowed optic nerve conduction consistent with demyelination even when the patient reports no visual symptoms. The 2017 McDonald Criteria for MS diagnosis, published in Lancet Neurology, incorporates EP evidence as supporting data for demonstrating dissemination in space.

Spinal cord compression — SSEPs assess dorsal column integrity in patients with cervical myelopathy or thoracic cord lesions. Surgeons also use intraoperative SSEPs to monitor spinal cord function during procedures; the ACNS has published dedicated intraoperative monitoring guidelines covering acceptable amplitude drop thresholds (typically a 50% decrease in amplitude or a 10% increase in latency triggers surgeon notification).

Brainstem and posterior fossa lesions — BAEPs localize dysfunction to the auditory nerve, cochlear nucleus, or pontine pathways through analysis of the five interpeak intervals. An absent wave V with preserved wave I, for example, points to a lesion rostral to the cochlear nucleus.

Hearing evaluation in non-communicative patients — BAEPs are used in neonates and comatose patients who cannot cooperate with behavioral audiometry, since the test requires no voluntary response.

Peripheral neuropathy distinction — When combined with EMG and nerve conduction studies, SSEPs help differentiate large-fiber peripheral neuropathy from dorsal column disease.

Decision boundaries

EP testing occupies a defined niche within the neurological workup, and its clinical utility depends on recognizing both its strengths and its boundaries.

EP studies are best suited to pathways with well-characterized normative latency data. They are less informative for disorders that primarily affect gray matter, disrupt axonal density without slowing conduction velocity, or produce lesions outside the tested pathway. A normal EP result does not exclude neurological disease; it excludes conduction slowing in the specific pathway tested on that day.

Compared to MRI of the brain and spine, EP studies offer functional rather than structural data. An MRI may show a lesion where EP is normal (if conduction is preserved), or EP may be abnormal where MRI is unremarkable (if demyelination has occurred without sufficient tissue destruction to appear on standard sequences). The two modalities are complementary, not redundant.

Patient cooperation requirements differ by modality: VEP demands sustained gaze fixation and adequate visual acuity; BAEP can be performed in sedated or comatose patients; SSEP requires only peripheral nerve stimulation tolerance. Patients with peripheral neuropathy may have technically compromised peripheral components of SSEP that limit central pathway interpretation.

Intraoperative EP monitoring carries specific safety considerations. Anesthetic agents, particularly inhalational agents, suppress cortical EP amplitudes and must be managed in coordination with the anesthesia team; total intravenous anesthesia (TIVA) protocols are commonly adopted to maintain signal quality during spine and brain surgery.

Billing and coverage for outpatient EP studies fall under CPT codes maintained by the American Medical Association. CMS reimbursement rules require physician supervision and interpretation by a qualified neurophysiologist, consistent with CMS transmittals governing electrodiagnostic testing.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)